Invention Application
- Patent Title: Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
-
Application No.: US13091498Application Date: 2011-04-21
-
Publication No.: US20110257153A1Publication Date: 2011-10-20
- Inventor: Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. Mcclure , Taraneh Mirzadegan , Alexandro Santillan, JR.
- Applicant: Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. Mcclure , Taraneh Mirzadegan , Alexandro Santillan, JR.
- Assignee: Janssen Pharmaceutical NV
- Current Assignee: Janssen Pharmaceutical NV
- Main IPC: A61K31/428
- IPC: A61K31/428 ; C12N9/99 ; C07D451/02 ; A61K31/46 ; A61K31/4995 ; C07D487/04 ; C07D471/04 ; A61K31/437 ; A61K31/4375 ; A61K31/5377 ; A61P29/00 ; A61P17/00 ; A61P11/06 ; A61P1/00 ; A61P9/10 ; A61P17/02 ; C07D487/08
Abstract:
Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
Public/Granted literature
- US08344008B2 Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase Public/Granted day:2013-01-01
Information query
IPC分类:
